Caprion/ImmuneCarta To Present At The GTC Bio Conference
Modeling Tumor-infiltrating Lymphocyte Dysfunction in-vitro
Using PBMC Isolated From HIV-infected Donors
Montreal, Canada, January 27, 2015 – Caprion today announced Yoav Peretz PhD., Scientific Director for ImmuneCarta®, the immune monitoring division of Caprion, will present a Case Study describing how HIV-specific T cells can help guide and prioritize the development of compounds aimed at restoring immune function in cancer and other chronic inflammatory conditions. Peretz will present on January 29th at 3:10 p.m. in the Immunomonitoring track at the 7th Immunotherapeutics & Immunomonitoring Conference to be held on January 29 – 30 in San Diego, CA.
PD-1 is a member of the CD28/CTLA-4 family of T cell regulators and is associated with the negative regulation of immune responses. Sustained expression and accumulation of these inhibitory receptors during chronic inflammation leads to T cell dysfunction also known as T cell exhaustion. Consequently, novel therapies that block the interaction of immune checkpoints with their ligands are being developed to treat various cancers. Using multi-parametric flow cytometry, phenotypic and functional data were obtained from PBMC isolated from chronic HIV-infected patients. The results demonstrate that checkpoints are upregulated and co-expressed on HIV-specific CD8+ T cells similar to what is observed in Tumour infiltrating Lymphocytes. These data suggest that PBMC isolated from HIV-infected donors can serve as a target cell population for identifying compounds that restore and enhance immune effector functions.
“We are excited to be implementing this screening tool for our pharmaceutical partners and facilitate the identification of immunotherapeutic agents for cancer using an approach which measures in-vitro functional restoration,” said Yoav Peretz, Ph.D., Scientific Director for ImmuneCarta.
About Caprion
Caprion is the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its immune monitoring business unit, ImmuneCarta®, offers proprietary multiparametric flow cytometry for functional analyses of innate and adaptive immune responses. Caprion’s proteomics business unit, ProteoCarta™, offers proprietary gel-free, label-free mass spectrometry (MS) for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Caprion also leverages ProteoCarta to develop its own in-vitro diagnostic products targeting cancer, metabolic and infectious diseases. With research sites in Montreal, Canada and in Menlo Park, CA, Caprion has been providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 10 years. Caprion, a privately-held company, is majority owned by Chicago Growth Partners. For more information, please visit www.caprion.com.
Help employers find you! Check out all the jobs and post your resume.
Montreal, Canada, January 27, 2015 – Caprion today announced Yoav Peretz PhD., Scientific Director for ImmuneCarta®, the immune monitoring division of Caprion, will present a Case Study describing how HIV-specific T cells can help guide and prioritize the development of compounds aimed at restoring immune function in cancer and other chronic inflammatory conditions. Peretz will present on January 29th at 3:10 p.m. in the Immunomonitoring track at the 7th Immunotherapeutics & Immunomonitoring Conference to be held on January 29 – 30 in San Diego, CA.
PD-1 is a member of the CD28/CTLA-4 family of T cell regulators and is associated with the negative regulation of immune responses. Sustained expression and accumulation of these inhibitory receptors during chronic inflammation leads to T cell dysfunction also known as T cell exhaustion. Consequently, novel therapies that block the interaction of immune checkpoints with their ligands are being developed to treat various cancers. Using multi-parametric flow cytometry, phenotypic and functional data were obtained from PBMC isolated from chronic HIV-infected patients. The results demonstrate that checkpoints are upregulated and co-expressed on HIV-specific CD8+ T cells similar to what is observed in Tumour infiltrating Lymphocytes. These data suggest that PBMC isolated from HIV-infected donors can serve as a target cell population for identifying compounds that restore and enhance immune effector functions.
“We are excited to be implementing this screening tool for our pharmaceutical partners and facilitate the identification of immunotherapeutic agents for cancer using an approach which measures in-vitro functional restoration,” said Yoav Peretz, Ph.D., Scientific Director for ImmuneCarta.
About Caprion
Caprion is the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its immune monitoring business unit, ImmuneCarta®, offers proprietary multiparametric flow cytometry for functional analyses of innate and adaptive immune responses. Caprion’s proteomics business unit, ProteoCarta™, offers proprietary gel-free, label-free mass spectrometry (MS) for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Caprion also leverages ProteoCarta to develop its own in-vitro diagnostic products targeting cancer, metabolic and infectious diseases. With research sites in Montreal, Canada and in Menlo Park, CA, Caprion has been providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 10 years. Caprion, a privately-held company, is majority owned by Chicago Growth Partners. For more information, please visit www.caprion.com.
Help employers find you! Check out all the jobs and post your resume.